Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPOX | P50336 | 1/20 | 0.41 |
| ▸ | S100A4 | P26447 | 2/20 | 0.41 |
| ▸ | MAPT | P10636 | 5/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.39 |
| ▸ | HPGD | P15428 | 2/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | TGM2 | P21980 | 1/20 | 0.38 |
| ▸ | CES1 | P23141 | 1/20 | 0.38 |
| ▸ | BCHE | P06276 | 1/20 | 0.38 |
| ▸ | AHR | P35869 | 1/20 | 0.38 |
| ▸ | PGR | P06401 | 1/20 | 0.36 |
| ▸ | BRD4 | O60885 | 1/20 | 0.36 |
| ▸ | ABCC9 | O60706 | 1/20 | 0.36 |
| ▸ | CTSD | P07339 | 1/20 | 0.36 |
| ▸ | BACE1 | P56817 | 1/20 | 0.36 |
| ▸ | MAOB | P27338 | 1/20 | 0.36 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5543907 | 0.79 | MAPT (0.37) | MAPTTDP1ALDH1A1HPGDKDM4E | |
| SCHEMBL12686425 | 0.79 | S100A4 (0.42) | PPOXS100A4ALDH1A1KDM4ETGM2 | |
| SCHEMBL23362956 | 0.78 | CA1 (0.43) | S100A4MAPTTDP1TGM2CES1 | |
| SCHEMBL29804089 | 0.78 | CA1 (0.43) | S100A4MAPTTDP1TGM2CES1 | |
| SCHEMBL5543912 | 0.78 | MAPT (0.58) | MAPTALDH1A1KDM4EMAOB | |
| SCHEMBL69403 | 0.74 | MAPT (0.67) | MAPTALDH1A1HPGDKDM4EMAOB | |
| SCHEMBL506797 | 0.74 | CA12 (0.36) | MAPTALDH1A1KDM4EMAOB | |
| SCHEMBL26179561 | 0.74 | PDK2 (0.44) | S100A4AHRPGRBACE1 | |
| SCHEMBL9221038 | 0.73 | ALDH1A1 (0.35) | MAPTTDP1ALDH1A1HPGDAHR | |
| SCHEMBL68917 | 0.72 | ALDH1A1 (0.50) | MAPTTDP1ALDH1A1HPGDKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 38 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2582674-B1 | GPR120 RECEPTOR AGONISTS AND USES THEREOF | CYMABAY THERAPEUTICS INC (US) | 2014-10-01 | — | — | EP | disclosed |
| EP-2582674-B1 | GPR120 RECEPTOR AGONISTS AND USES THEREOF | CYMABAY THERAPEUTICS INC (US) | 2014-10-01 | — | — | EP | disclosed |
| US-20140121246-A1 | GPR120 RECEPTOR AGONISTS AND USES THEREOF | METABOLEX, INC. (US) | 2014-05-01 | — | — | US | disclosed |
| US-8598374-B2 | GPR120 receptor agonists and uses thereof | METABOLEX, INC. (US) | 2013-12-03 | — | — | US | disclosed |
| US-8476308-B2 | GPR120 receptor agonists and uses thereof | METABOLEX, INC. (US) | 2013-07-02 | — | — | US | disclosed |
| US-8476308-B2 | GPR120 receptor agonists and uses thereof | METABOLEX, INC. (US) | 2013-07-02 | — | — | US | disclosed |
| US-8476308-B2 | GPR120 receptor agonists and uses thereof | METABOLEX, INC. (US) | 2013-07-02 | — | — | US | disclosed |
| US-20130131351-A1 | GPR120 RECEPTOR AGONISTS AND USES THEREOF | METABOLEX, INC. (US) | 2013-05-23 | — | — | US | disclosed |
| US-20130131351-A1 | GPR120 RECEPTOR AGONISTS AND USES THEREOF | METABOLEX, INC. (US) | 2013-05-23 | — | — | US | disclosed |
| US-20130131351-A1 | GPR120 RECEPTOR AGONISTS AND USES THEREOF | METABOLEX, INC. (US) | 2013-05-23 | — | — | US | disclosed |
| US-20110313003-A1 | GPR120 RECEPTOR AGONISTS AND USES THEREOF | METABOLEX, INC. | 2011-12-22 | — | — | US | disclosed |
| EP-2367793-A1 | GPR120 RECEPTOR AGONISTS AND USES THEREOF | Metabolex Inc. (US) | 2011-09-28 | — | — | EP | disclosed |
| US-20100190831-A1 | GPR120 RECEPTOR AGONISTS AND USES THEREOF | METABOLEX, INC. | 2010-07-29 | — | — | US | disclosed |
| US-20100190831-A1 | GPR120 RECEPTOR AGONISTS AND USES THEREOF | METABOLEX, INC. | 2010-07-29 | — | — | US | disclosed |
| US-20100190831-A1 | GPR120 RECEPTOR AGONISTS AND USES THEREOF | METABOLEX, INC. | 2010-07-29 | — | — | US | disclosed |
| WO-2010080537-A1 | GPR120 RECEPTOR AGONISTS AND USES THEREOF | METABOLEX, INC. (US) | 2010-07-15 | — | — | WO | disclosed |
| WO-2010080537-A1 | GPR120 RECEPTOR AGONISTS AND USES THEREOF | METABOLEX, INC. (US) | 2010-07-15 | — | — | WO | disclosed |
| US-4874869-A | TREATMENT OF DIABETIC COMPLICATIONS, CATARACTS | EISAI CO., LTD. (JP) | 1989-10-17 | — | — | US | disclosed |
| US-4780472-A | Hydantoin derivatives for treating complications of diabetes | EISAI CO., LTD. (JP) | 1988-10-25 | — | — | US | disclosed |
| US-4540704-A | Treating complications of diabetes mellitus with hydantoin derivatives | EISAI CO., LTD. (JP) | 1985-09-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110313003-A1 | GPR120 RECEPTOR AGONISTS AND USES THEREOF | GPR119, GPR52, GCGR | PPOX 4386/4885S100A4 4362/4885MAPT 4135/4885 |
| US-20100190831-A1 | GPR120 RECEPTOR AGONISTS AND USES THEREOF | GPR119, GPR52, GCGR | PPOX 4386/4885S100A4 4362/4885MAPT 4135/4885 |
| US-20140121246-A1 | GPR120 RECEPTOR AGONISTS AND USES THEREOF | GPR119, GPR52, GCGR | PPOX 4386/4885S100A4 4362/4885MAPT 4135/4885 |
| US-20130131351-A1 | GPR120 RECEPTOR AGONISTS AND USES THEREOF | GPR119, GPR52, GCGR | PPOX 4386/4885S100A4 4362/4885MAPT 4135/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.